IP Library Granted Patent US 12,403,094
Granted Patent B2
US 12,403,094 · App. 17/225,149 · Granted Sep 2, 2025

Rheological solid oral composition

Inventors: Matthew Lawrence Lynch (Mariemont, OH); Scott Kendyl Stanley (Mason, OH); Brandon Philip Illie (Felicity, OH); Taotao Zhu (West Chester, OH); Jamie Lynn Dria (Deerfield Township, OH); Ashraf Traboulsi (West Chester, OH)
Assignee: The Procter & Gamble Company
A61K9/2013A61K9/282A61K31/137A61K31/138A61K31/167A61K31/4402A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,094
App. No.
17/225,149
Granted
Sep 2, 2025
Kind
B2
Abstract

A rheological solid oral composition comprising a crystallizing agent, an aqueous phase, and an oral active agent.

Claims (31)

1. A rheological solid oral composition for delivering an oral active agent, comprising:

a crystallizing agent comprising a blend of salts of fatty acids containing from 13 to 16 carbon atoms; wherein the crystallizing agent blend has an Optimal Purity (Po) of greater than about 0.3 and a Single Purity (Ps) of greater than about 0.5;

an aqueous phase comprising water and a solvent; and

an oral active agent;

wherein the rheological solid composition comprises from about 80% to about 99.5% water and about 0.5% to about 15% solvent, by weight of the rheological solid oral composition;

wherein the rheological solid oral composition has a crystalline mesh comprising a rigid,

three-dimensional, interlocking crystalline skeleton framework of fiber-like crystalline particles formed from crystallizing agents, and the framework has voids or openings containing the aqueous phase and the oral active agent.

2. The rheological solid oral composition according to claim 1 , having a firmness between 0.1 N and 50.0 N as determined by FIRMNESS TEST METHOD, and having a thermal stability of about 40° C. to about 95° C. as determined by THERMAL STABILITY TEST METHOD, and having a liquid expression of between about 100 J m-3 to about 6000 J m-3 as determined by AQUEOUS PHASE EXPRESSION TEST METHOD.

3. The rheological solid oral composition according to claim 1 , wherein the crystallizing agent comprises a blend of salts of fatty acids containing 13 or 14 carbon atoms.

4. The rheological solid oral composition according to claim 1 , wherein the crystallizing agent is a metal salt.

5. The rheological solid oral composition according to claim 4 , wherein the metal salt is at least one of sodium palmitate or sodium myristate.

6. The rheological solid oral composition according to claim 1 , wherein the crystallizing agent is present in an amount from about 0.01% to about 10%, by weight of the rheological solid oral composition.

7. The rheological solid oral composition according to claim 1 , wherein the oral active agent is at least one of Antacids, H2 Antagonists, Proton Pump Inhibitors, Anesthetics, Antibiotics, Anticholinergics, Antihistamines, Antitussives, Antivirals, Decongestants, Demulcents, Expectorants, Mucolytics, Pain-Relieving Agents, Sleep Agents, or Dietary Supplements.

8. The rheological solid oral composition according to claim 7 , wherein the Dietary Supplement is at least one Allergy Supplement Ingredients, Antioxidant Supplement Ingredients, Digestive Wellness/Gastrointestinal Ingredients, Enzymes, Immune Agents, Metabolics, Vitamins, Minerals, Neurologics, Pain Reducers, Sleep Agents, Stress Agents, Prebiotics, or Probiotics.

9. The rheological solid oral composition according to claim 7 wherein the Pain-Relieving Agent is acetaminophen.

10. The rheological solid oral composition according to claim 1 wherein the oral active agent is less than about 10% of the weight of the dosage form.

11. The rheological solid oral composition according to claim 1 , having a static coefficient of friction of less than about 0.50.

12. A rheological solid oral composition for delivering an oral active agent, comprising:

a crystallizing agent comprising a blend of salts of fatty acids containing from 13 to 16 carbon atoms; wherein the crystallizing agent blend has an Optimal Purity (Po) of greater than about 0.3 and a Single Purity (Ps) of greater than about 0.5;

an aqueous phase comprising water and a solvent; and

an oral active agent;

wherein, the rheological solid oral composition has a firmness between about 0.1 N to about 50.0 N as determined by FIRMNESS TEST METHOD;

a thermal stability of about 40° C. to about 95° C. as determined by THERMAL STABILITY TEST METHOD;

a liquid expression of between about 100 J m-3 to about 8,000 J m-3 as determined by AQUEOUS PHASE EXPRESSION TEST METHOD;

wherein the oral active agent is at least one of Antacids, H2 Antagonists, Proton Pump Inhibitors, Anesthetics, Antibiotics, Anticholinergics, Antihistamines, Antitussives, Antivirals, Decongestants, Demulcents, Expectorants, Mucolytics, Pain-Relieving Agents, Sleep Agents, or Dietary Supplements; and

wherein the rheological solid composition comprises from about 80% to about 99.5% water and about 0.5% to about 15% solvent, by weight of the rheological solid oral composition;

wherein the rheological solid oral composition has a crystalline mesh comprising a rigid,

three-dimensional, interlocking crystalline skeleton framework of fiber-like crystalline particles formed from crystallizing agents, and the framework has voids or openings containing the aqueous phase and the oral active agent.

13. The rheological solid oral composition according to claim 12 , wherein the Dietary Supplement is at least one Allergy Supplement Ingredients, Antioxidant Supplement Ingredients, Digestive Wellness/Gastrointestinal Ingredients, Enzymes, Immune Agents, Metabolics, Vitamins, Minerals, Neurologics, Pain Reducers, Sleep Agents, Stress Agents, Prebiotics, or Probiotics.

14. The rheological solid oral composition according to claim 11 , wherein the crystallizing agent is a metal salt.

15. The rheological solid oral composition according to claim 12 , having a static coefficient of friction of less than about 0.50.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2021
From: LYNCH, MATTHEW LAWRENCE; STANLEY, SCOTT KENDYL; ILLIE, BRANDON PHILIP; ZHU, TAOTAO; DRIA, JAMIE LYNN; TRABOULSI, ASHRAF
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 055873/0727 →
Continuity (2)
Provisional Application 63007969 · Apr 10, 2020
Related Publication 20210322322A1 · Oct 21, 2021
References Cited (155)
US 823725A · Hayden · 1906 [cited by applicant]
US 3112219A · Alfred · 1963 [cited by applicant]
US 3293684A · Otto · 1966 [cited by applicant]
US 3585144A · Schiltz · 1971 [cited by applicant]
US 3810841A · Richter · 1974 [cited by applicant]
US 3956158A · Donaldson · 1976 [cited by applicant]
US 4107289A · Kaufman · 1978 [cited by applicant]
US 4203857A · Dugan · 1980 [cited by applicant]
US 4226889A · Yuhas · 1980 [cited by examiner]
US 4322400A · Yuhas · 1982 [cited by applicant]
US 4486404A · Weinert · 1984 [cited by applicant]
US 4806340A · Gaffar · 1989 [cited by applicant]
US 4808467A · Suskind et al. · 1989 [cited by applicant]
US 5144729A · Austin et al. · 1992 [cited by applicant]
US 5160739A · Kanga · 1992 [cited by applicant]
US 5340492A · Kacher · 1994 [cited by examiner]
US 5340571A · Grace · 1994 [cited by applicant]
US 5425892A · Taneri et al. · 1995 [cited by applicant]
US 5436278A · Imashiro et al. · 1995 [cited by applicant]
US 5525397A · Shizuno et al. · 1996 [cited by applicant]
US 5585092A · Trandai et al. · 1996 [cited by applicant]
US 5605681A · Trandai · 1997 [cited by examiner]
US 5691035A · Chappell et al. · 1997 [cited by applicant]
US 5846520A · Guskey et al. · 1998 [cited by applicant]
US 5916590A · Cody · 1999 [cited by examiner]
US 6042815A · Kellner et al. · 2000 [cited by applicant]
US 6143393A · Abe et al. · 2000 [cited by applicant]
US 6241835B1 · Abe et al. · 2001 [cited by applicant]
US 6245413B1 · Kenmochi et al. · 2001 [cited by applicant]
US 6329308B1 · Kenmochi et al. · 2001 [cited by applicant]
US 6550092B1 · Brown et al. · 2003 [cited by applicant]
US 6554937B1 · Kenmochi et al. · 2003 [cited by applicant]
US 6774070B1 · Kenmochi et al. · 2004 [cited by applicant]
US 6777064B1 · Brown et al. · 2004 [cited by applicant]
US 6797357B2 · Fereshtehkhou et al. · 2004 [cited by applicant]
US 6813801B2 · Tanaka et al. · 2004 [cited by applicant]
US 6936330B2 · Fereshtehkhou et al. · 2005 [cited by applicant]
US 7003856B2 · Hayashi et al. · 2006 [cited by applicant]
US 7041277B2 · Holme · 2006 [cited by applicant]
US 7291359B2 · Haskett et al. · 2007 [cited by applicant]
US 7386907B2 · Otsuka et al. · 2008 [cited by applicant]
US 7560398B2 · Zillig et al. · 2009 [cited by applicant]
US 7566671B2 · Hoadley et al. · 2009 [cited by applicant]
US 7712178B2 · Yamada · 2010 [cited by applicant]
US 7779502B2 · Fujiwara et al. · 2010 [cited by applicant]
US 7937797B2 · Tsuchiya et al. · 2011 [cited by applicant]
US 8075977B2 · Curro et al. · 2011 [cited by applicant]
US 8093192B2 · Liu et al. · 2012 [cited by applicant]
US 8146197B2 · Yamada · 2012 [cited by applicant]
US 8151402B2 · Takabayashi et al. · 2012 [cited by applicant]
US 8161594B2 · Policicchio et al. · 2012 [cited by applicant]
US 8186001B2 · Tsuchiya et al. · 2012 [cited by applicant]
US 8225453B2 · Yamada · 2012 [cited by applicant]
US 8245349B2 · Tsuchiya et al. · 2012 [cited by applicant]
US 8435625B2 · Ruehe et al. · 2013 [cited by applicant]
US 8528151B2 · Przepasniak · 2013 [cited by applicant]
US 8536074B2 · Fereshtehkhou et al. · 2013 [cited by applicant]
US 8617685B2 · Yamada · 2013 [cited by applicant]
US 8646144B2 · Wada et al. · 2014 [cited by applicant]
US 8752232B2 · Otsuka et al. · 2014 [cited by applicant]
US 8756746B2 · Policicchio · 2014 [cited by applicant]
US 8763197B2 · Policicchio et al. · 2014 [cited by applicant]
US 8793832B2 · Yamada · 2014 [cited by applicant]
US 8851776B2 · Schwarz et al. · 2014 [cited by applicant]
US 8858971B2 · Rao · 2014 [cited by applicant]
US 9113768B2 · Wada et al. · 2015 [cited by applicant]
US 9198553B2 · Policicchio · 2015 [cited by applicant]
US 9204775B2 · Pung et al. · 2015 [cited by applicant]
US 9296176B2 · Escaffre et al. · 2016 [cited by applicant]
US 9339165B2 · Vetter et al. · 2016 [cited by applicant]
US 9622943B2 · Scala et al. · 2017 [cited by applicant]
US 10076583B2 · Lynch · 2018 [cited by applicant]
US 10143764B2 · Lynch · 2018 [cited by applicant]
US 10383825B2 · Lebo et al. · 2019 [cited by applicant]
US 10821056B2 · Swartz et al. · 2020 [cited by applicant]
US 10835455B2 · Payne et al. · 2020 [cited by applicant]
US 10932996B2 · Baig et al. · 2021 [cited by applicant]
US 11812909B2 · Lynch · 2023 [cited by applicant]
US 20010048933A1 · L'Alloret · 2001 [cited by applicant]
US 20020160088A1 · Sakaguchi et al. · 2002 [cited by applicant]
US 20030021760A1 · Kumar et al. · 2003 [cited by applicant]
US 20030053980A1 · Dodd et al. · 2003 [cited by applicant]
US 20040185011A1 · Alexander · 2004 [cited by applicant]
US 20050152851A1 · Kaminski · 2005 [cited by applicant]
US 20060024245A1 · Gebreselassie et al. · 2006 [cited by applicant]
US 20090155190A1 · Gebreselassie et al. · 2009 [cited by applicant]
US 20100061941A1 · Gebreselassie · 2010 [cited by applicant]
US 20110027328A1 · Baig et al. · 2011 [cited by applicant]
US 20110053826A1 · Wise · 2011 [cited by applicant]
US 20110262507A1 · Spring · 2011 [cited by applicant]
US 20130111682A1 · Pung · 2013 [cited by applicant]
US 20130302385A1 · Muenz et al. · 2013 [cited by applicant]
US 20140289984A1 · Vetter · 2014 [cited by applicant]
US 20150196185A1 · Fiske · 2015 [cited by applicant]
US 20150313803A1 · Lynch et al. · 2015 [cited by applicant]
US 20150313808A1 · Lynch et al. · 2015 [cited by applicant]
US 20160051684A1 · Wang · 2016 [cited by applicant]
US 20160120771A1 · Simonet et al. · 2016 [cited by applicant]
US 20160346175A1 · Sasik et al. · 2016 [cited by applicant]
US 20180127692A1 · Coope-Epstein et al. · 2018 [cited by applicant]
US 20190160022A1 · Chiou · 2019 [cited by applicant]
US 20190298625A1 · Hilliard, Jr. et al. · 2019 [cited by applicant]
US 20190343732A1 · Mao · 2019 [cited by applicant]
US 20200000693A1 · Traynor et al. · 2020 [cited by applicant]
US 20210007940A1 · Swartz et al. · 2021 [cited by applicant]
CA 680113A · 1964 [cited by applicant]
CN 107440935A · 2017 [cited by applicant]
DE 202007001353U1 · 2007 [cited by applicant]
EP 0916722A2 · 1999 [cited by applicant]
EP 2465487A2 · 2012 [cited by applicant]
EP 2170257B1 · 2012 [cited by applicant]
ES 2548699T3 · 2015 [cited by applicant]
GB 2221389A · 1990 [cited by applicant]
WO 9209679A1 · 1992 [cited by applicant]
WO 0196461A1 · 2001 [cited by applicant]
WO 03075735A1 · 2003 [cited by applicant]
WO 2007133265A2 · 2007 [cited by applicant]
WO 2009095891A1 · 2009 [cited by applicant]
WO 2010060653A2 · 2010 [cited by applicant]
WO 2014124066A1 · 2014 [cited by applicant]
Saper, Am Fam Physician, 79, 9, 2009 (Year: 2009). [cited by examiner]
PCT Search Report and Written Opinion for PCT/US2021/026301 dated Jul. 5, 2021. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/196,379. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,146. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,148. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,150. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,151. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,153. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,176. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/225,218. [cited by applicant]
Clinton D. Stevenson, et al. ,“Capillary Pressure as Related to Water Holding in Polyacrylamide and Chicken Protein Gels”, Journal of Food Science, vol. 78, Nr. 2, dated 2013,pp. C145-C151. [cited by applicant]
F. V. Ryer, Oil & Soap, “Research Laboratory, Lever Brothers Company Cambridge, Massachusetts”, dated Oct. 1946, pp. 310-313. [cited by applicant]
F. V. Ryer, et al. Growing Single Crystals, “A Method of Growing Single Crystals of Sodium Stearate and Sodium Palmitate”, dated Feb. 4, 1944, pp. 154-158. [cited by applicant]
Marc N. G. de Mul, et al. Langmuir 2000, “Solution Phase Behavior and Solid Phase Structure of Long-Chain Sodium Soap Mixtures”, vol. 16, No. 22, dated 2000, pp. 8276-8284. [cited by applicant]
Masao Sambuichi, et al. Dewatering of Gels, “Filtration, Food Chemical Engineering, Solid Liquid Separation, Dewatering, Expression, Gel”, Journal of Chemical Engineering of Japan, vol. 27, No. 5, dated 1994, pp. 616-62… [cited by applicant]
Matthew L Lynch, Acid-soaps, “The study of acid-soap crystals has resulted in many conflicting data”, Current Opinion in Colloid & Interface Science, dated 1997,pp. 495-500. [cited by applicant]
Matthew L. Lynch, et al. Acid-soap crystals, “Spectroscopic and Thermal Characterization of 1:2 Sodium Soap/Fatty Acid Acid-Soap Crystals”, J. Phys. Chem., vol. 100, No. 1, 1996, pp. 357-361. [cited by applicant]
Matthew L. Lynch, Structure of Fatty Acid-Soap Crystals,“Intermolecular Interactions and the Structure of Fatty Acid-Soap Crystals”, J. Phys. Chem. B, vol. 105, No. 2, dated 2001, pp. 552-561. [cited by applicant]
Theodore P. Labuza, et al. , “Measurement of Gel Water-Binding Capacity by Capillary Suction Potential”, Journal of Food Science, vol. 43, dated 1978 ,pp. 1264-1269. [cited by applicant]
Unpublished U.S. Appl. No. 17/196,379, filed Mar. 9, 2021, to first inventor Geoffrey Marc Wise. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,150, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,218, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,147, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch. et al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,151, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,153, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,176, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
Unpublished U.S. Appl. No. 17/225,148, filed Apr. 8, 2021, to first inventor Matthew Lawrence Lynch et. al. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/485,906, filed Sep. 27, 2021. [cited by applicant]
Unpublished U.S. Appl. No. 17/485,906, filed Sep. 27, 2021, to first inventor et. al. [cited by applicant]
All Office Actions; U.S. Appl. No. 18/450,176, filed Aug. 15, 2023. [cited by applicant]
Unpublished U.S. Appl. No. 18/450,176, filed Aug. 15, 2023, to Matthew Lawrence Lynch et. al. [cited by applicant]
All Office Actions; U.S. Appl. No. 18/909,337, filed Oct. 8, 2024. [cited by applicant]
All Office Actions; U.S. Appl. No. 18/909,342, filed Oct. 8, 2024. [cited by applicant]
Unpublished U.S. Appl. No. 18/909,337, filed Oct. 8, 2024, Matthew Lawrence Lynch et al. [cited by applicant]
Unpublished U.S. Appl. No. 18/909,342, filed Oct. 8, 2024, Matthew Lawrence Lynch et al. [cited by applicant]